clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02135614 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
Belgium | Q31 | ||
Poland | Q36 | ||
Italy | Q38 | ||
Netherlands | Q55 | ||
France | Q142 | ||
United Kingdom | Q145 | ||
Australia | Q408 | ||
New Zealand | Q664 | ||
Israel | Q801 | ||
P582 | end time | 2017-03-27 | |
P2899 | minimum age | 18 | |
P1132 | number of participants | 189 | |
P6153 | research site | University of Washington | Q219563 |
Tel Aviv University | Q319239 | ||
Soonchunhyang University | Q484622 | ||
Monash University | Q598841 | ||
NewYork–Presbyterian Hospital | Q975653 | ||
Griffith University | Q1202292 | ||
Rabin Medical Center | Q2071553 | ||
hôpital Foch | Q3145155 | ||
Tenon Hospital | Q3145241 | ||
Seoul National University Hospital | Q4403855 | ||
Asan Medical Center | Q4803501 | ||
Henry Ford Health System | Q5721418 | ||
Northwestern Memorial Hospital | Q7060339 | ||
Waikato Hospital | Q7959998 | ||
Westmead Hospital | Q7989074 | ||
Rochester General Hospital | Q28229048 | ||
P580 | start time | 2014-06-09 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection |
Search more.